MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapies, announced today that it has appointed Mr. Kevin Taylor as its Chief Business Officer. Mr. Taylor will report directly to Hing C. Wong, Ph.D., Chief Executive Officer of Altor.
“I am delighted to welcome Kevin to Altor and look forward to working with him,” remarked Dr. Wong. “Kevin will strengthen our key existing business relationships and focus on finding, executing and fostering new partnering opportunities for Altor.”
Mr. Taylor brings over 20 years of experience in corporate and business development to Altor. He previously was the Chief Business Officer of Nuron Biotech and held business development leadership roles at Cangene Corporation, Adolor Corporation and Codexis. Earlier in his career he held senior positions at Elan Corporation, AstraZeneca and Zeneca, Inc. Mr. Taylor has extensive experience leading partnering initiatives and structuring collaborations. Over the last ten years, he has concluded a number of partnering and M&A transactions with specialty and multinational pharmaceuticals companies, including Cubist Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Mitsubishi-Tanabe Pharma, Novartis, Pfizer, Schering-Plough and Teva Pharmaceuticals.
About Altor BioScience
Altor is a privately held biotechnology company developing immunotherapies for treating cancer, viral infections, and inflammatory diseases based on its proprietary soluble T-cell receptor, Interleukin-15 superagonist and Tissue Factor antagonist platform technologies. Altor currently has four Phase I and two Phase II trials underway for its immunotherapeutics against cancer.
Visit www.altorbioscience.com for details.
